The efficacy of cefoperazone sulbactam combined with ambroxol hydrochloride in the treatment of chronic obstructive pulmonary disease
头孢哌酮舒巴坦联合盐酸氨溴索治疗慢阻肺的疗效

摘要

目的 探究分析头孢哌酮舒巴坦联合盐酸氨溴索治疗慢阻肺的疗效。方法 选取于2023年1月至2024年1月期间，院内慢阻肺患者共102例，以患者出生日期为基础，应用随机分组的方式，将102例患者随机分为对照组与观察组。对照组采用头孢哌酮舒巴坦治疗，观察组采用头孢哌酮舒巴坦联合盐酸氨溴索治疗，对比两组治疗效果，肺功能指标；血气指标以及生活质量。结果 观察组治疗效果以及生活质量高于对照组，P＜0.05。两组肺功能指标，血气指标治疗前无明显差异，P＞0.05，治疗后观察组优于对照组，P＜0.05。结论 头孢哌酮舒巴坦联合盐酸氨溴索可显著改善患者肺功能指标以及血气指标，确保患者治疗效果以及生活质量的可持续提升。

Abstract

Objective To explore and analyze the efficacy of cefoperazone and sulbactam combined with ambroxol hydrochloride in the treatment of chronic obstructive pulmonary disease.
Methods A total of 102 patients with COPD in the hospital from January 2023 to January 2024 were selected. Based on the patient's date of birth, the 102 patients were randomly divided into the control group and the observation group using random grouping. The control group was treated with cefoperazone-sulbactam, and the observation group was treated with cefoperazone-sulbactam combined with ambroxol hydrochloride. The treatment effects, lung function indicators, blood gas indicators, and quality of life of the two groups were compared.
Results The treatment effect and quality of life of the observation group were higher than those of the control group, P<0.05. There was no significant difference in lung function indicators and blood gas indicators between the two groups before treatment, P>0.05. After treatment, the observation group was better than the control group, P<0.05.
Conclusion   Cefoperazone-sulbactam combined with ambroxol hydrochloride can significantly improve patients' pulmonary function indicators and blood gas indicators, ensuring the sustainable improvement of patients' treatment effects and quality of life.